A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

por Hájek, R, Masszi, T, Petrucci, M T, Palumbo, A, Rosiñol, L, Nagler, A, Yong, K L, Oriol, A, Minarik, J, Pour, L, Dimopoulos, M A, Maisnar, V, Rossi, D, Kasparu, H, Van Droogenbroeck, J, Yehuda, D B, Hardan, I, Jenner, M, Calbecka, M, Dávid, M, de la Rubia, J, Drach, J, Gasztonyi, Z, Górnik, S, Leleu, X, Munder, M, Offidani, M, Zojer, N, Rajangam, K, Chang, Y-L, San-Miguel, J F, Ludwig, H
Publicado 2017